Natco Pharma (NSE:NATCOPHARM) Cyclically Adjusted Book per Share: ₹0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NATCOPHARM Natco Pharma Ltd NSE:NATCOPHARM
88 GF Score
Price ₹838.30
GF Value ₹819.80
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Natco Pharma Cyclically Adjusted Book per Share?

Natco Pharma NSE:NATCOPHARM -0.70% 88 Cyclically Adjusted Book per Share is ₹0.00 as of Jun. 2026. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 88/100 and a GF Value™ of ₹819.80 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Natco Pharma's adjusted book value per share for the three months ended in Jun. 2026 was ₹0.000. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Natco Pharma's average Cyclically Adjusted Book Growth Rate was 19.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 18.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 18.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Natco Pharma was 23.50% per year. The lowest was 18.60% per year. And the median was 18.85% per year.

As of today (2026-09-04), Natco Pharma's current stock price is ₹838.30. Natco Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was ₹0.00. Natco Pharma's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Natco Pharma was 8.79. The lowest was 2.89. And the median was 4.74.


Natco Pharma  (NSE:NATCOPHARM) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Natco Pharma was 8.79. The lowest was 2.89. And the median was 4.74.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Natco Pharma Cyclically Adjusted Book per Share Related Terms


Natco Pharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Natco Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natco Pharma Cyclically Adjusted Book per Share Chart

Natco Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 149.76 178.74 210.97 250.53 299.11

Natco Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 276.20 0.00 299.11 0.00

NSE:NATCOPHARM vs ZTS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Cyclically Adjusted PB Ratio falls into.


NSE:NATCOPHARM
88GF Score
Natco Pharma Ltd NSE:NATCOPHARM
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natco Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Natco Pharma's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Natco Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201609 80.370 105.961 126.938
201612 0.000 105.196 0.000
201703 94.620 105.196 150.532
201706 0.000 107.109 0.000
201709 103.862 109.021 159.437
201712 0.000 109.404 0.000
201803 166.521 109.786 253.843
201806 0.000 111.317 0.000
201809 185.074 115.142 269.003
201812 0.000 115.142 0.000
201903 190.921 118.202 270.317
201906 0.000 120.880 0.000
201909 202.598 123.175 275.269
201912 0.000 126.235 0.000
202003 207.258 124.705 278.145
202006 0.000 127.000 0.000
202009 223.162 130.118 287.030
202012 0.000 130.889 0.000
202103 226.042 131.771 287.088
202106 0.000 134.084 0.000
202109 231.915 135.847 285.709
202112 0.000 138.161 0.000
202203 233.596 138.822 281.613
202206 0.000 142.347 0.000
202209 250.404 144.661 289.690
202212 0.000 145.763 0.000
202303 267.101 146.865 304.371
202306 0.000 150.280 0.000
202309 295.545 151.492 326.497
202312 0.000 152.924 0.000
202403 326.788 153.035 357.373
202406 0.000 155.789 0.000
202409 399.190 157.882 423.147
202412 0.000 158.323 0.000
202503 424.711 157.552 451.144
202506 0.000 159.755 0.000
202509 482.932 162.289 498.013
202512 0.000 163.281 0.000
202603 514.829 164.272 524.497
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ₹0.00 mean?
Natco Pharma (NSE:NATCOPHARM) has a Cyclically Adjusted Book per Share of ₹0.00 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Natco Pharma and its competitors.
Is Natco Pharma's Cyclically Adjusted Book per Share too high?
Natco Pharma's current Cyclically Adjusted Book per Share is ₹0.00. Overall, Natco Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's Cyclically Adjusted Book per Share compare to ZTS?
Natco Pharma's Cyclically Adjusted Book per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Natco Pharma and its competitors. Natco Pharma's current Cyclically Adjusted Book per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹819.80, compared to a current price of ₹838.30 — trading 2.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is ₹0.00. Natco Pharma's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current Cyclically Adjusted Book per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Natco Pharma stock appears to be overvalued. The current stock price of ₹838.30 is trading 2.3% above its estimated GF Value™ of ₹819.80. GuruFocus considers Natco Pharma to be Fairly Valued.

Key valuation signals for NSE:NATCOPHARM:

  • Cyclically Adjusted Book per Share: ₹0.00
  • GF Value™: ₹819.80 vs. price of ₹838.30 (2.3% above fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Natco Pharma Business Description

Other Exchanges 524816:India
Address Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
88GF Score

Get the complete analysis for NSE:NATCOPHARM

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹838.30
Price
₹819.80
GF Value